Evidence map›Paper›PMID 35897812›Full record

ArticleInternational journal of molecular sciences2022

Effect of Chemically Modified Carbon-Coated Iron Nanoparticles on the Structure of Human Atherosclerotic Plaques Ex Vivo and on Adipose Tissue in Chronic Experiment In Vivo.

Shamil Akhmedov, Sergey Afanasyev, Natalia Beshchasna, Marina Trusova, Ivan Stepanov, Mariya Rebenkova, Ekaterina Poletykina, Yuri Vecherskiy, Sergei Tverdokhlebov, Evgeny Bolbasov and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Shamil AkhmedovCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
Sergey AfanasyevCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
Natalia BeshchasnaFraunhofer Institute for Ceramic Technologies and Systems IKTS, 01109 Dresden, Germany.
Marina TrusovaResearch School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
Ivan StepanovCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
Mariya RebenkovaCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
Ekaterina PoletykinaResearch School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
Yuri VecherskiyCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
Sergei TverdokhlebovSchool of Nuclear Science and Engineering, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0002-2242-6358
Evgeny BolbasovSchool of Nuclear Science and Engineering, Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0002-9789-2185
Sascha BalakinFraunhofer Institute for Ceramic Technologies and Systems IKTS, 01109 Dresden, Germany.ORCID 0000-0001-6169-8746
Joerg OpitzFraunhofer Institute for Ceramic Technologies and Systems IKTS, 01109 Dresden, Germany.ORCID 0000-0003-3142-2479
Anatoly YermakovM.N. Miheev Institute of Metal Physics of Ural Branch of Russian Academy of Sciences, 620108 Ekaterinburg, Russia.
Boris KozlovCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.ORCID 0000-0002-0217-7737
Russian Academy of Sciences · RUNational Research Tomsk State University · RUFraunhofer Institute for Ceramic Technologies and Systems · DEM.N. Mikheev Institute of Metal Physics · RU

Funding

Federal Ministry of Education and Research 01DJ21012Russian Foundation for Basic Research 20-53-76012 ERA
6 · The paper itself

Abstract

The high mortality rate caused by atherosclerosis makes it necessary to constantly search for new and better treatments. In previous reports, chemically modified carbon-coated iron nanoparticles (Fe@C NPs) have been demonstrated a high biocompatibility and promising anti-plaque properties. To further investigate these effects, the interaction of these nanoparticles with the adipose tissue of Wistar rats (in vivo) and human atherosclerotic plaques (ex vivo) was studied. For the in vivo study, cobalt-chromium (CoCr) alloy tubes, which are used for coronary stent manufacturing, were prepared with a coating of polylactic acid (PLA) which contained either modified or non-modified Fe@C NPs in a 5% by weight concentration. The tubes were implanted into an area of subcutaneous fat in Wistar rats, where changes in the histological structure and functional properties of the surrounding tissue were observed in the case of coatings modified with Fe@C NPs. For the ex vivo study, freshly explanted human atherosclerotic plaques were treated in the physiological solution with doses of modified Fe@C NPs, with mass equal to 5% or 25% relative to the plaques. This treatment resulted in the release of cholesterol-like compounds from the surface of the plaques into the solution, thus proving a pronounced destructive effect on the plaque structure. Chemically modified Fe@C NPs, when used as an anti-atherosclerosis agent, were able to activate the activity of macrophages, which could lead to the destruction of atherosclerotic plaques structures. These findings could prove the fabrication of next-generation vascular stents with built-in anti-atherosclerotic agents.

Indexed as

AtherosclerosisNanoparticlesPlaque, AtheroscleroticAdipose TissueAnimalsCarbonHumansIronRatsRats, WistarCarbonIronatherosclerosisatherosclerotic plaquechemically modified carbon-coated iron nanoparticlecoronary stentmacrophagereverse cholesterol transport

Identifiers

PMID35897812
PMCPMC9331237
OpenAlexW4288042348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.